Cancer Research AACR Legacy Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, X.
Right arrow Articles by Kang, Y. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, X.
Right arrow Articles by Kang, Y. J.
[Cancer Research 61, 3382-3387, April 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Attenuation of Doxorubicin Chronic Toxicity in Metallothionein-overexpressing Transgenic Mouse Heart1

Xiuhua Sun, Zhanxiang Zhou and Y. James Kang2

Departments of Medicine, and Pharmacology and Toxicology, University of Louisville, School of Medicine, [X. S., Z. Z., Y. J. K.], and Jewish Hospital Heart and Lung Institute [Y. J. K.], Louisville, Kentucky 40202

Previous studies have shown that cardiac-specific metallothionein (MT)-overexpressing transgenic mice are highly resistant to acute cardiotoxicity induced by doxorubicin (DOX), a most effective anticancer agent. However, cumulative dose-dependent chronic cardiotoxicity attributable to long-term administration of DOX is a significant clinical problem. Because MT is a potent antioxidant and oxidative stress is critically involved in DOX-induced heart injury, the present study was undertaken to test the hypothesis that MT also provides protection against DOX chronic cardiotoxicity. Transgenic mice containing high levels of cardiac MT and nontransgenic controls were treated with a cumulative dose of 40 mg/kg of DOX in 10 equal i.v. injections over a period of 7 weeks. Three weeks after the last injection, the mice were killed for an analysis of cardiotoxicity. As compared with nontransgenic controls, DOX-induced cardiac hypertrophy was significantly inhibited in the transgenic mice. Light microscopic examination revealed that DOX-induced myocardial morphological changes were markedly suppressed or almost eliminated in the transgenic mice. Under electron microscopy, extensive sarcoplasmic vacuolization and severe disruption of mitochondrial fine structure were observed in nontransgenic cardiomyocytes, but almost no sarcoplasmic vacuolization was observed, and the mitochondrial structural changes were almost completely prevented in the transgenic cardiomyocytes. The results thus indicate that MT elevation is a highly effective approach to prevent chronic cardiomyopathy attributable to DOX. This study also suggests that oxidative stress is critically involved in the DOX-induced chronic cardiotoxicity.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J. Niu, A. Azfer, K. Wang, X. Wang, and P. E. Kolattukudy
Cardiac-Targeted Expression of Soluble Fas Attenuates Doxorubicin-Induced Cardiotoxicity in Mice
J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 740 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
K. Y. Wonders, D. S. Hydock, C. M. Schneider, and R. Hayward
Acute Exercise Protects Against Doxorubicin Cardiotoxicity
Integr Cancer Ther, September 1, 2008; 7(3): 147 - 154.
[Abstract] [PDF]

Home page
 Exp. Biol. Med.Home page
E. Grasselli, L. Canesi, A. Voci, R. De Matteis, I. Demori, E. Fugassa, and L. Vergani
Effects of 3,5-Diiodo-L-Thyronine Administration on the Liver of High Fat Diet-Fed Rats
Experimental Biology and Medicine, May 1, 2008; 233(5): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. Frank, C. Kuhn, B. Brors, C. Hanselmann, M. Ludde, H. A. Katus, and N. Frey
Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program
Hypertension, February 1, 2008; 51(2): 309 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. Deng, B. Kulle, M. Hosseini, G. Schluter, G. Hasenfuss, L. Wojnowski, and A. Schmidt
Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity
Eur J Heart Fail, October 1, 2007; 9(10): 986 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Mol. Interv., June 1, 2007; 7(3): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
K. E. Merten, Y. Jiang, and Y. J. Kang
Zinc Inhibits Doxorubicin-Activated Calcineurin Signal Transduction Pathway in H9c2 Embryonic Rat Cardiac Cells
Experimental Biology and Medicine, May 1, 2007; 232(5): 682 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
C. Ojaimi, K. Qanud, T. H. Hintze, and F. A. Recchia
Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs
Physiol Genomics, March 14, 2007; 29(1): 76 - 83.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Merten, Y. Jiang, W. Feng, and Y. J. Kang
Calcineurin Activation Is Not Necessary for Doxorubicin-Induced Hypertrophy in H9c2 Embryonic Rat Cardiac Cells: Involvement of the Phosphoinositide 3-Kinase-Akt Pathway
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 934 - 940.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
Y. J. Kang
Metallothionein redox cycle and function.
Experimental Biology and Medicine, October 1, 2006; 231(9): 1459 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Wang, Y. Song, L. Elsherif, Z. Song, G. Zhou, S. D. Prabhu, J. T. Saari, and L. Cai
Cardiac Metallothionein Induction Plays the Major Role in the Prevention of Diabetic Cardiomyopathy by Zinc Supplementation
Circulation, January 31, 2006; 113(4): 544 - 554.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Feng, F. W. Benz, J. Cai, W. M. Pierce, and Y. J. Kang
Metallothionein Disulfides Are Present in Metallothionein-overexpressing Transgenic Mouse Heart and Increase under Conditions of Oxidative Stress
J. Biol. Chem., January 13, 2006; 281(2): 681 - 687.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Merten, W. Feng, L. Zhang, W. Pierce, J. Cai, J. B. Klein, and Y. J. Kang
Modulation of Cytochrome c Oxidase-Va Is Possibly Involved in Metallothionein Protection from Doxorubicin Cardiotoxicity
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1314 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
L. Xie, G. Tsaprailis, and Q. M. Chen
Proteomic Identification of Insulin-like Growth Factor-binding Protein-6 Induced by Sublethal H2O2 Stress from Human Diploid Fibroblasts
Mol. Cell. Proteomics, September 1, 2005; 4(9): 1273 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Wang, Z. Zhou, J. T. Saari, and Y. J. Kang
Alcohol-Induced Myocardial Fibrosis in Metallothionein-Null Mice: Prevention by Zinc Supplementation
Am. J. Pathol., August 1, 2005; 167(2): 337 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Q. M. Chen, D. Alexander, H. Sun, L. Xie, Y. Lin, J. Terrand, S. Morrissy, and S. Purdom
Corticosteroids Inhibit Cell Death Induced by Doxorubicin in Cardiomyocytes: Induction of Antiapoptosis, Antioxidant, and Detoxification Genes
Mol. Pharmacol., June 1, 2005; 67(6): 1861 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
M. Kannan, L. Wang, and Y. J. Kang
Myocardial Oxidative Stress and Toxicity Induced by Acute Ethanol Exposure in Mice
Experimental Biology and Medicine, June 1, 2004; 229(6): 553 - 559.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. J. Kang, Y. Li, X. Sun, and X. Sun
Antiapoptotic Effect and Inhibition of Ischemia/Reperfusion-Induced Myocardial Injury in Metallothionein-Overexpressing Transgenic Mice
Am. J. Pathol., October 1, 2003; 163(4): 1579 - 1586.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
X. Sun and Y. J. Kang
Prior Increase in Metallothionein Levels Is Required to Prevent Doxorubicin Cardiotoxicity
Experimental Biology and Medicine, September 1, 2002; 227(8): 652 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Z. Zhou, X. Sun, J. C. Lambert, J. T. Saari, and Y. J. Kang
Metallothionein-Independent Zinc Protection from Alcoholic Liver Injury
Am. J. Pathol., June 1, 2002; 160(6): 2267 - 2274.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. C. Tu, J. J. Bahl, and Q. M. Chen
Signals of Oxidant-Induced Cardiomyocyte Hypertrophy: Key Activation of p70 S6 Kinase-1 and Phosphoinositide 3-Kinase
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1101 - 1110.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.